| abstract |
The present invention relates to a composition for preventing, alleviating or treating respiratory diseases, containing a Siraitia grosvenorii residual extract as an active ingredient. In an ovalbumin (OVA) induced asthma animal model, a Siraitia grosvenorii residual extract of the present invention has effects of reducing airway hypersensitivity, inhibiting inflammatory cells in bronchoalveolar lavage fluid and reducing Th2 cytokines (IL-4, IL-5 and IL-13) in bronchoalveolar lavage fluid, reducing inflammation and tissue damage in lung tissue, inhibiting airway smooth muscle contraction and airway inflammation, inhibiting the expression of IL-13, TARC, TNF-a, IL-17 and mucus gene MUC5AC in lung tissue, and reducing, in alveolar cells, ROS having increased because of fine dust. |